糖胃康治疗糖尿病性胃轻瘫的临床研究

目的探讨糖胃康对糖尿病性胃轻瘫（diabetic gastroparesis，DGP）的临床疗效及作用机理。方法选择90例糖尿病性胃轻瘫患者随机分组，其中30例予降糖治疗与糖胃康治疗（治疗组），30例予降糖治疗与吗丁啉治疗（对照组），30例予降糖治疗（空白对照组），观察各组临床疗效、胃动素（MOT）及胃排空率等变化。结果糖胃康可以明显改善DGP患者的临床症状，增加胃排空率，改善胃肠蠕动功能，明显缩短胃排空时间，有利于血糖（餐后2h血糖及果糖胺）的控制；治疗组治愈率63．33％（19例），与对照组（26．67％，8例）及空白组（10．00％，3例）比较，差异有显著性（P〈0．01）；总有效率93．33％，与对照组（63．33％）及空白组（33．33％）比较，差异有显著性（P〈0．01）；治疗组疗效优于其他两组。结论糖胃康对DGP具有良好的治疗效果。 医疗法

Clinical Study on Tangweikang in Treating Diabetic Gastroparesis

ObjectiveTo investigate clinical effects and mechanism of Tangweikang(TWK)in treating diabetic gastroparesis.MethodsNinety diabetic gastroparesis patients were randomly assigned to 3 groups.Besides conventional hypoglycemic treatment,the 30 patients in the treated group were given TWK and the 30 in the control group were given Domperidone additionally,while to the 30 in the blank group,no additional drug was given.The clinical efficacy and the changes in level of motilin and gastric emptying rate were observed.ResultsTWK showed significant effects in improving clinical symptoms of patients,increasing gastric emptying rate,promoting gastrointestinal kinetics,shortening gastric emptying time and was beneficial to the control of blood sugar,including the 2 h post-prandial blood sugar and fructosamine.The curative rate and total effective rate in the treated group were 63.33%(19/30)and 93.33%(29/30)respectively,significantly different to those in the control group 26.67%(8/30)and 63.33%,also different to those in the blank group 23.33%(3/30)and 10.00%,respectively(P<0.01).The clinical efficacy in the treated group was superior to that in the other two groups.ConclusionTWK has favorable therapeutic efficacy in treating DGP.